2023 Myotonic Dystrophy Foundation Early Career Research Grant
Grants to provide two-year awards to early-career researchers in Myotonic dystrophy.
The Myotonic Dystrophy Foundation (MDF) will issue up to two two-year awards of up to $380,000 at $190,000 per award for early career scholars in the DM field for projects that focus on basic, translational and/or clinical research or care projects in myotonic dystrophy.
Further information:
Application Due:
Applications are due by September 9, 2022, with a start date for successful applicants of January 2023.
Applicants are encouraged to contact MDF’s Chief Executive Officer, Dr. Tanya Stevenson, with any questions about this RFA or the scientific content of their proposals. Technical issues should be directed to MDF’s Research Coordinator Dr. Nadine Ann Skinner.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.